Uzun, O., Wilson, D. G., Vujanic, G. M., Parsons, J. M. & De Giovanni, J. V. Cardiac tumours in children. Orphanet J. Rare Dis. 2, 11 (2007).

Article  PubMed  PubMed Central  Google Scholar 

Isaacs, H. Fetal and neonatal cardiac tumors. Pediatr. Cardiol. 25, 252–273 (2004).

Article  PubMed  Google Scholar 

Northrup, H. et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr. Neurol. 123, 50–66 (2021).

Article  PubMed  Google Scholar 

Huang, J. & Manning, B. D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 412, 179–190 (2008).

Article  CAS  PubMed  Google Scholar 

Hinton, R. B. et al. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J. Am. Heart Assoc. 3, e001493 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Bornaun, H. et al. Regression of cardiac rhabdomyomas in a neonate after Everolimus treatment. Case Rep. Pediatr. 2016, 8712962 (2016).

PubMed  PubMed Central  Google Scholar 

Nespoli, L. F. et al. Efficacy of Everolimus low-dose treatment for cardiac Rhabdomyomas in neonatal tuberous sclerosis: case report and literature review. Pediatr. Rep. 13, 104–112 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Dahdah, N. Everolimus for the Treatment of Tuberous Sclerosis Complex-Related Cardiac Rhabdomyomas in Pediatric Patients. J. Pediatr. 190, 21–6.e7 (2017).

Article  PubMed  Google Scholar 

Fesslova, V., Villa, L., Rizzuti, T., Mastrangelo, M. & Mosca, F. Natural history and long-term outcome of cardiac rhabdomyomas detected prenatally. Prenat. Diagn. 24, 241–248 (2004).

Article  PubMed  Google Scholar 

Jóźwiak, S. et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics 118, e1146–e1151 (2006).

Article  PubMed  Google Scholar 

Chao, A. S. et al. Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis. Ultrasound Obstet. Gynecol. 31, 289–295 (2008).

Article  CAS  PubMed  Google Scholar 

Aw, F. et al. Accelerated cardiac Rhabdomyoma regression with Everolimus in infants with tuberous Sclerosis complex. Pediatr. Cardiol. 38, 394–400 (2017).

Article  PubMed  Google Scholar 

Stelmaszewski, E. V. et al. Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial. Cardiol. Young-.-. 30, 337–345 (2020).

Article  PubMed  Google Scholar 

Garg, A., Gorla, S. R., Kardon, R. E. & Swaminathan, S. Rapid Involution of Large Cardiac Rhabdomyomas With Everolimus Therapy. World J. Pediatr. Congenit. Heart Surg. 12, 426–429 (2021).

Article  PubMed  Google Scholar 

Hoshal, S. G., Samuel, B. P., Schneider, J. R., Mammen, L. & Vettukattil, J. J. Regression of massive cardiac rhabdomyoma on everolimus therapy. Pediatr. Int. 58, 397–399 (2016).

Article  PubMed  Google Scholar 

Sugalska, M., Tomik, A., Jóźwiak, S. & Werner, B. Treatment of cardiac Rhabdomyomas with mTOR inhibitors in children with tuberous Sclerosis complex-a systematic review. Int J. Environ. Res Public Health 18, 4907 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, X. et al. Treatment strategies for primary tumors of the heart in children: a 10-year experience. Ann. Thorac. Surg. 100, 1744–1749 (2015).

Article  PubMed  Google Scholar 

Franz, D. N. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381, 125–132 (2013).

Article  CAS  PubMed  Google Scholar 

Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817–824 (2013).

Article  CAS  PubMed  Google Scholar 

Bevacqua, M. et al. Off-Label use of Sirolimus and Everolimus in a pediatric center: a case series and review of the literature. Paediatr. Drugs 21, 185–193 (2019).

Article  CAS  PubMed  Google Scholar 

Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Moola, S. et al. Systematic reviews of etiology and risk (2020). In JBI Manual for Evidence Synthesis (Aromataris, E., Lockwood, C., Porritt, K., Pilla, B. & Jordan, Z., eds) https://synthesismanual.jbi.global (JBI, 2024).

French, J. A. et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388, 2153–2163 (2016).

Article  CAS  PubMed  Google Scholar 

Cleary, A. & McMahon, C. J. Literature review of international mammalian target of rapamycin inhibitor use in the non-surgical management of haemodynamically significant cardiac rhabdomyomas. Cardiol. Young-.-. 30, 923–933 (2020).

Article  PubMed  Google Scholar 

Mizuno, T. et al. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur. J. Pharm. Sci. 109S, S124–S131 (2017).

Article  PubMed  Google Scholar 

Ng, L. Y. et al. Cardiac Rhabdomyomas presenting with critical cardiac obstruction in neonates and infants: treatment strategies and outcome, a single-center experience. Pediatr. Cardiol. 45, 1132–1141 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharm. Ther. 138, 103–141 (2013).

Article  CAS  Google Scholar 

Hines, R. N. Ontogeny of human hepatic cytochromes P450. J. Biochem Mol. Toxicol. 21, 169–175 (2007).

Article  CAS  PubMed  Google Scholar 

Emoto, C. et al. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants. CPT Pharmacomet. Syst. Pharm. 5, 411–417 (2016).

Article  CAS  Google Scholar 

MacKeigan, J. P. & Krueger, D. A. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 17, 1550–1559 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takada, T. et al. Efficacy and safety of long-term Sirolimus Therapy for Asian patients with Lymphangioleiomyomatosis. Ann. Am. Thorac. Soc. 13, 1912–1922 (2016).

Article  PubMed  Google Scholar 

Jóźwiak, S., Kotulska, K., Berkowitz, N., Brechenmacher, T. & Franz, D. N. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial. J. Pediatr. 172, 151–155.e1 (2016).

Article  PubMed  Google Scholar 

Saffari, A. et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study. Orphanet J. Rare Dis. 14, 96 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. (Engl. Ed.). 112, 90–92 (2021).

Article  CAS  PubMed